Clinical Trial Results:
An Interventional, Efficacy and Safety, Phase 2, Randomized, Double-Blind, 2-arm Study to Investigate a Repeat 5-day Course of Nirmatrelvir/Ritonavir Compared to Placebo/Ritonavir in Participants at Least 12 Years of age with Rebound of COVID-19 Symptoms and Rapid Antigen Test Positivity
Summary
|
|
EudraCT number |
2022-002827-36 |
Trial protocol |
DE GR IT |
Global end of trial date |
09 Feb 2024
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Aug 2024
|
First version publication date |
02 Aug 2024
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
C4671042
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT05567952 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Pfizer Inc.
|
||
Sponsor organisation address |
66 Hudson Boulevard Est, New York, United States, NY 10001
|
||
Public contact |
Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
|
||
Scientific contact |
Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
18 Oct 2023
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
09 Feb 2024
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To compare the effect of nirmatrelvir/ritonavir to placebo/ritonavir on viral ribonucleic acid (RNA) level in nasopharyngeal (NP) swabs in participants with mild-to-moderate coronavirus disease 2019 (COVID-19).
|
||
Protection of trial subjects |
The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials participants were followed.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
19 Oct 2022
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety | ||
Long term follow-up duration |
6 Months | ||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Canada: 2
|
||
Country: Number of subjects enrolled |
Greece: 1
|
||
Country: Number of subjects enrolled |
Taiwan: 7
|
||
Country: Number of subjects enrolled |
United States: 426
|
||
Worldwide total number of subjects |
436
|
||
EEA total number of subjects |
1
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
1
|
||
Adults (18-64 years) |
313
|
||
From 65 to 84 years |
116
|
||
85 years and over |
6
|
|
||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||
Recruitment details |
- | |||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||
Screening details |
A total of 436 participants were randomized and treated in this study to evaluate the efficacy and safety of a repeat 5-day treatment course of nirmatrelvir/ritonavir or placebo/ritonavir for the treatment of mild-to moderate COVID-19. | |||||||||||||||||||||
Period 1
|
||||||||||||||||||||||
Period 1 title |
Overall Period
|
|||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||
Roles blinded |
Subject, Investigator, Carer | |||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
Nirmatrelvir 300 mg + Ritonavir 100 mg | |||||||||||||||||||||
Arm description |
Participants received nirmatrelvir 300 milligrams (mg) (participants with estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 30 to less than [<] 60 millilitre per minute [mL/min]/1.73 meters squared [m^2] [or estimated creatinine clearance [CrCl] >=30 to <60 mL/min] received 150 mg every 12 hours [q12h] for 5 days at screening) and ritonavir 100 mg, orally for 5 days q12h from Day 1 to Day 5. | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Nirmatrelvir
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||
Dosage and administration details |
Participants received Nirmatrelvir 300 mg q12h for 5 days, as oral dose.
|
|||||||||||||||||||||
Investigational medicinal product name |
Ritonavir
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
|||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||
Dosage and administration details |
Participants received Ritonavir 100 mg q12h for 5 days, as oral dose.
|
|||||||||||||||||||||
Arm title
|
Placebo + Ritonavir 100 mg | |||||||||||||||||||||
Arm description |
Participants received placebo matched to nirmatrelvir followed by ritonavir 100 mg orally, for 5 days q12h from Day 1 to Day 5. | |||||||||||||||||||||
Arm type |
Placebo | |||||||||||||||||||||
Investigational medicinal product name |
Ritonavir
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
|||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||
Dosage and administration details |
Participants received Ritonavir 100 mg q12h for 5 days, as oral dose.
|
|||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||
Dosage and administration details |
Participants received placebo q12h for 5 days, as oral dose.
|
|||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nirmatrelvir 300 mg + Ritonavir 100 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received nirmatrelvir 300 milligrams (mg) (participants with estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 30 to less than [<] 60 millilitre per minute [mL/min]/1.73 meters squared [m^2] [or estimated creatinine clearance [CrCl] >=30 to <60 mL/min] received 150 mg every 12 hours [q12h] for 5 days at screening) and ritonavir 100 mg, orally for 5 days q12h from Day 1 to Day 5. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo + Ritonavir 100 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received placebo matched to nirmatrelvir followed by ritonavir 100 mg orally, for 5 days q12h from Day 1 to Day 5. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Nirmatrelvir 300 mg + Ritonavir 100 mg
|
||
Reporting group description |
Participants received nirmatrelvir 300 milligrams (mg) (participants with estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 30 to less than [<] 60 millilitre per minute [mL/min]/1.73 meters squared [m^2] [or estimated creatinine clearance [CrCl] >=30 to <60 mL/min] received 150 mg every 12 hours [q12h] for 5 days at screening) and ritonavir 100 mg, orally for 5 days q12h from Day 1 to Day 5. | ||
Reporting group title |
Placebo + Ritonavir 100 mg
|
||
Reporting group description |
Participants received placebo matched to nirmatrelvir followed by ritonavir 100 mg orally, for 5 days q12h from Day 1 to Day 5. |
|
|||||||||||||
End point title |
Change From Baseline to Day 5 in Viral Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA Level in NP Swabs - mITT Population | ||||||||||||
End point description |
Baseline was defined as the latest measurement between Day -1 and Day 1, but post-dose samples that are collected within 1 hour post start of dosing were treated as baseline. Samples with result "less than (<) lower limit of quantification (LLOQ)" are imputed as 1.7 log10 copies/milliliter (mL), and samples with result "Not Detected" are imputed as 0.0 log10 copies/mL. Modified intent-to-treat (mITT) analysis population included all participants randomly assigned to study intervention who took at least 1 dose of study intervention and who had a positive viral RNA NP swab test result (>= 2.0 log10 copies per mL) at baseline. Here, 'Number of Subjects Analysed (N)' signifies participants evaluable for this endpoint.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline, Day 5
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Nirmatrelvir300+Ritonavir100/Placebo+Ritonavir100 | ||||||||||||
Statistical analysis description |
Mixed model for repeated measures (MMRM) included fixed effects of treatment, geographic region, baseline SARS-CoV-2 RNA level, visit, and treatment-by-visit interaction; an unstructured (co) variance structure was used.
|
||||||||||||
Comparison groups |
Nirmatrelvir 300 mg + Ritonavir 100 mg v Placebo + Ritonavir 100 mg
|
||||||||||||
Number of subjects included in analysis |
331
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0004 | ||||||||||||
Method |
MMRM | ||||||||||||
Parameter type |
Least square (LS) mean difference | ||||||||||||
Point estimate |
-0.705
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-1.093 | ||||||||||||
upper limit |
-0.316 |
|
|||||||||||||
End point title |
Time to Two Consecutive Negative Rapid Antigen Test (RAT) Results At Least 24 Hours (hrs) Apart Through Day 28- mITT Population | ||||||||||||
End point description |
The event of 2 consecutive negative RAT results obtained at least 24 (-2) hrs apart through Day 28 was defined as achieving 2 consecutive non-missing RATs with negative results through Day 28, where the 2 tests are at least 22 hours and at most 7 days apart. For the event of 2 consecutive negative RAT results obtained at least 24 hrs apart through Day 28, the date of the first negative RAT result was considered the first event date. Time to 2 consecutives negative RAT results obtained at least 24 hrs apart defined as: for participant achieving event, time to event = (first event date) -(first dose date) + 1. For participant not achieving event (censored), censoring date was at last date of RAT measurement, time = (censoring date)-(first dose date) + 1 or Day 27 whichever occurred first (Day 27 was last possible day to achieve 2 consecutive negative RAT results obtained at least 24 hrs apart through Day 28). mITT analysis set evaluated. 'N'= participants evaluable for this endpoint.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 1 of dosing maximum up to Day 28
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Nirmatrelvir300+Ritonavir100/Placebo+Ritonavir100 | ||||||||||||
Statistical analysis description |
Analysis was based on Cox proportional hazard (PH) model which included treatment, geographic region, baseline SARS-CoV-2 RNA level (< 4 log10 copies/mL or >= 4 log10 copies/mL) and time since the last vaccination (less than or equal to [<=6] months, > 6 months or unvaccinated) as appropriate.
|
||||||||||||
Comparison groups |
Nirmatrelvir 300 mg + Ritonavir 100 mg v Placebo + Ritonavir 100 mg
|
||||||||||||
Number of subjects included in analysis |
338
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0697 | ||||||||||||
Method |
COX proportional hazard model | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
1.235
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.983 | ||||||||||||
upper limit |
1.551 |
|
|||||||||||||
End point title |
Time to Sustained Alleviation of All Targeted Signs and Symptoms Through Day 28- mITT Population | ||||||||||||
End point description |
Sustained alleviation of all targeted COVID-19 signs/symptoms was defined as the event occurring on the first of 2 consecutive days when all symptoms scored as moderate or severe at study entry are scored as mild or absent and all symptoms scored mild or absent at study entry are scored as absent. The first day of the 2 consecutive-day period was considered the first event date. The time to sustained symptom alleviation was defined as for a participant with sustained symptom alleviation, time to event was calculated as (First Event Date) – (First Dose Date) +1. For a participant that either completed Day 28 of the study or discontinued from the study before Day 28 without sustained symptom alleviation (censored), censoring date was at the last date on which symptom alleviation was assessed, and time was calculated as (Censoring Date) – (First Dose Date) +1 or Day 27 whichever occurred first. mITT analysis set evaluated. 'N'=participants evaluable for this endpoint.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 1 of dosing maximum up to Day 28
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Nirmatrelvir300+Ritonavir100/Placebo+Ritonavir100 | ||||||||||||
Statistical analysis description |
Analysis was based on Cox proportional hazard (PH) model which included treatment, geographic region, baseline SARS-CoV-2 RNA level (< 4 log10 copies/mL or >= 4 log10 copies/mL) and time since the last vaccination (<=6 months, > 6 months or unvaccinated) as appropriate.
|
||||||||||||
Comparison groups |
Nirmatrelvir 300 mg + Ritonavir 100 mg v Placebo + Ritonavir 100 mg
|
||||||||||||
Number of subjects included in analysis |
285
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.5202 | ||||||||||||
Method |
COX proportional hazard model | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
1.084
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.848 | ||||||||||||
upper limit |
1.385 |
|
|||||||||||||||||||
End point title |
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation From Study | ||||||||||||||||||
End point description |
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic. TEAEs were defined as AE that started on or after study medication on Day 1 up to Week 24 follow-up. AEs included both SAEs and all non-SAEs. Safety population included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Day 1 of dosing maximum up to Week 24 follow-up
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Day 1 of dosing maximum up to Week 24 follow-up
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
An event may be categorized as serious in 1 participant and non-serious in other, or a participant may experience both serious and non-serious event. Safety population: all participants randomly assigned to study intervention, who took at least 1 dose of study intervention.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
v26.1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nirmatrelvir 300 mg + Ritonavir 100 mg
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Enter Description here | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo + Ritonavir 100 mg
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Enter Description here | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
16 Sep 2022 |
The population in the estimands and the primary analysis population was updated with the requirement of a positive rapid antigen test at baseline to align with the inclusion/exclusion criteria.
Endpoint of: ‘Proportion of participants with SARS-CoV-2 RNA in NP swabs below the LLOQ (defined as <2.0 log10 copies/mL) on both Days 5 and 10’. Removed as a secondary endpoint and added as a tertiary/exploratory endpoint.
New secondary endpoint/estimand of: ‘Time to 2 consecutive negative rapid antigen test results.’ Added. The corresponding analysis for secondary endpoints were updated /added with more details.
Updated sample size assumptions and the corresponding calculation to reflect the change in the primary analysis population.
Amended to add self-administered daily rapid antigen tests for all study days between scheduled visits until 2 consecutive negative rapid antigen test results are obtained at which point, rapid antigen testing will be performed only at remaining scheduled visits.
Text describing Tables 4 and 5 was revised to clarify DDI table content. Tables were updated with information from the Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid (August 2022). |
||
12 May 2023 |
Primary and secondary estimands and the mITT analysis set description have been updated to include that participants must have a positive viral RNA NP swab test result at baseline.
Sample size calculation updated. |
||
29 Jun 2023 |
Additional secondary analyses for primary and secondary efficacy endpoints using the new analysis set (mITT1). Update the multiplicity adjustment accordingly. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |